Clinical Trials Logo

Pure Red Cell Aplasia, Acquired clinical trials

View clinical trials related to Pure Red Cell Aplasia, Acquired.

Filter by:
  • None
  • Page 1

NCT ID: NCT04470804 Completed - Clinical trials for Pure Red Cell Aplasia, Acquired

Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA

PRCA
Start date: July 1, 2020
Phase: Phase 4
Study type: Interventional

Pure red cell aplasia (PRCA) is a kind of anemia characterized by severe reticulocytopenia and obvious bone marrow erythroblastic cells decreased. Cyclosporine A and /or steroids are the first line therapy but some patients were refractory or intolerance to the treatment. The effects of the second line therapy are also not satisfactory and sometimes not available. The investigators aim to explore the efficacy and side-effect of sirolimus for newly diagnosed primary acquired PRCA.